Dendritic cells migrating from carcinogen-treated skin have reduced antigen-presenting function.
Ragg
S J
SJ
Department of Pathology, University of Tasmania, Hobart, Australia.
Dandie
G W
GW
Woods
G M
GM
Muller
H K
HK
D015127:9,10-Dimethyl-1,2-benzanthracene / Q000633:toxicity; D000818:Animals; D017951:Antigen Presentation / Q000187:drug effects*; D000941:Antigens / Q000008:administration & dosage; D002273:Carcinogens / Q000633:toxicity*; D002465:Cell Movement / Q000187:drug effects; D003713:Dendritic Cells / Q000187:drug effects / Q000276:immunology* / Q000502:physiology*; D066298:In Vitro Techniques; D007801:Langerhans Cells / Q000187:drug effects / Q000276:immunology / Q000502:physiology; D008196:Lymph / Q000166:cytology / Q000276:immunology; D008213:Lymphocyte Activation; D010047:Ovalbumin / Q000008:administration & dosage / Q000276:immunology; D012756:Sheep; D012867:Skin / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology
D000941:Antigens; D002273:Carcinogens; D015127:9,10-Dimethyl-1,2-benzanthracene; D010047:Ovalbumin